AVI BioPharma, Inc. (AVII) Tops Q3 EPS by 3c; Guides FY11 Sales
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Join SI Premium – FREE
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q3 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06).
Sees FY2011 revenue of $40-$50 million, versus the consensus of $54.18 million.
Sees FY2011 revenue of $40-$50 million, versus the consensus of $54.18 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- InspireMD (NSPR) Tops Q2 EPS by 1c
- Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
